Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Steroid Treatment for Myasthenia Gravis
Muscle Nerve 25:115-121, Rivner,M.H., 2002
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
The Dilemma of Delirium:Clin & Research Contro in Dx Eval in Hosp Elderly Pts
Am J Med 97:278-288, Inouye,S.K., 1994
Metastatic spinal cord compression
BMJ 342:d2402, Quraishi, N. & Esler, C., 2011
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
HIV-1 Protease Inhibitors
JAMA 227:145-149, Deeks,S.J.,et al, 1997
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care
Neurol 45:569-572, Gunderson,C.H., 1995
Magnetic Resonance Imaging in Brachial Plexopathy of Cancer
Neurol 45:421-427, Thyagarajan,D.,et al, 1995
Consensus Statement:Benefits VS Risk of Medical Therapy for Acromegaly
Am J Med 97:468-473, Melmed,S.,et al, 1994